Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%The Motley Fool • 09/11/25
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in FocusZacks Investment Research • 08/08/25
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 08/07/25
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 08/01/25
INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 07/31/25
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company UpdatesGlobeNewsWire • 07/31/25
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?Benzinga • 07/30/25
With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'Seeking Alpha • 07/18/25
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?Zacks Investment Research • 06/25/25
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology CongressGlobeNewsWire • 06/15/25
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%Zacks Investment Research • 06/04/25
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy StudyZacks Investment Research • 05/30/25
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On CourseBenzinga • 05/29/25
INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 05/23/25